Intas Pharmaceuticals, a vertically integrated pharma company, on Sunday said it expects to launch its first biosimilar in the US within 9-12 months.
Intas is the only domestic firm with two biosimilars filed for registration in the US and it looks to deliver affordable and innovative pharmaceutical solutions in India, the company said in a statement.
It is the only company from India to have launched a biosimilar in European market, Intas added. Its first biosimilar, Accofil (filgratsim) was launched in Europe earlier this year.
The company expects to launch its first biosimilar in the US within 9-12 months, it said.
For the domestic market, Intas has launched a Made in India molecule Razumab at a price 25% cheaper than the imported Lucentis.
It is the first company globally to develop and launch a biosimilar version of ranibizumab.
The molecule is manufactured under strict guidelines for sterile use in the eye and is offered as single dose vial, thus reducing the risk of contamination during use.
“Razumab will be sold at about 25% cheaper than the imported Lucentis. This would lead to an annual saving of about Rs 35,000 or more in the cost of treatment to the patient,” Intas Vice Chairman Binish Chudgar said.
Razumab is the 10th biosimilar launched by Intas in India, by far the largest number of indigenously developed biosimilars by any company.
Intas is ranked 11th in the domestic pharma market with 2.66% market share.
The company has presence in more than 70 countries, including North America, Europe, South Africa, Australia and New Zealand.